List of Excipients in Branded Drug MECAMYLAMINE HYDROCHLORIDE

Generic Drugs Containing MECAMYLAMINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Nexgen Pharma Inc	mecamylamine hydrochloride	0722-7183	D&C YELLOW NO. 10
Nexgen Pharma Inc	mecamylamine hydrochloride	0722-7183	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
Nexgen Pharma Inc	mecamylamine hydrochloride	0722-7183	FD&C YELLOW NO. 6
Nexgen Pharma Inc	mecamylamine hydrochloride	0722-7183	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in MECAMYLAMINE HYDROCHLORIDE?

# Of NDCs	Excipient
2	D&C YELLOW NO. 10
2	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
2	FD&C YELLOW NO. 6
2	LACTOSE MONOHYDRATE

Mecamylamine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Mecamylamine hydrochloride is an old, low-dose ganglionic nicotinic receptor antagonist with limited current hypertension demand and no meaningful remaining composition-of-matter exclusivity. The strongest commercial opportunities are low-cost generic supply, patient-friendly reformulation, specialty products for research or orphan-like indications, and combination products. The main formulation challenge is dose uniformity at the 2.5 mg strength, together with taste, gastrointestinal tolerability, and the drug’s broad autonomic adverse-effect profile.

What is the regulatory status of mecamylamine hydrochloride?

Mecamylamine hydrochloride was approved in the United States as an oral antihypertensive under the Inversine brand. The conventional product is a 2.5 mg tablet. Mecamylamine is a long-acting, orally active ganglionic blocker that inhibits transmission at autonomic ganglia.

Attribute	Information
Active ingredient	Mecamylamine hydrochloride
Therapeutic class	Ganglionic nicotinic receptor antagonist
Historical indication	Hypertension
Conventional strength	2.5 mg tablet
Administration	Oral
Original brand	Inversine
FDA pathway	Legacy NDA product; generic approval pathway available
Current commercial status	Limited and historically inconsistent availability
Biosimilar relevance	None; this is a small-molecule drug
Primary formulation issue	Low-dose content uniformity and tolerability

The original hypertension indication is commercially constrained because mecamylamine can cause orthostatic hypotension, constipation, urinary retention, blurred vision, dry mouth, and other anticholinergic-like autonomic effects. Modern antihypertensive classes have largely displaced ganglionic blockers.

FDA labeling identifies mecamylamine as a potent ganglionic blocker with dose-related adverse reactions and substantial interaction risks with other blood-pressure-lowering agents.[1]

What patents protect mecamylamine hydrochloride?

No commercially significant active composition-of-matter patent is expected to remain for mecamylamine hydrochloride. The drug entered clinical use in the 1950s, placing the original active-ingredient protection well beyond the standard U.S. patent term.

The remaining intellectual-property opportunity is therefore likely to arise from:

• New dosage forms
• Modified-release systems
• Taste-masked oral products
• Combination products
• New therapeutic uses
• Manufacturing processes
• Solid-state or particle-engineering claims
• Device-assisted administration
• Patient-specific dosing systems

A basic 2.5 mg immediate-release tablet is unlikely to support durable patent protection unless it includes a technically distinctive formulation or manufacturing process.

How many patents cover mecamylamine hydrochloride?

The commercially relevant patent estate appears narrow compared with newer small-molecule products. Patent diligence should separate historical patents from potentially enforceable rights in each jurisdiction.

IP category	Commercial relevance
Original compound patents	Expired
Original hypertension-use patents	Expired
Basic immediate-release tablet claims	Weak unless tied to a novel process
Modified-release claims	Potentially valuable
Taste-masking claims	Potentially valuable for pediatric or geriatric use
Combination therapy claims	Potentially valuable but indication-dependent
New-method-of-use claims	Possible for smoking cessation, neuropsychiatric disorders, or addiction research
Manufacturing claims	Potential value if they reduce impurities or improve yield
Trademark protection	Limited value relative to formulation protection

A current freedom-to-operate review should examine U.S. Patent and Trademark Office records, FDA Orange Book listings, WIPO PatentScope, and national registers in Europe, Canada, Japan, Australia, and emerging markets. Patent claims directed only to mecamylamine itself should be treated as expired unless an unusual term adjustment or jurisdiction-specific right applies.

When does mecamylamine hydrochloride lose exclusivity?

Mecamylamine hydrochloride has already lost its original exclusivity. The practical market-entry barriers are regulatory execution, supply economics, product liability, clinical positioning, and distribution rather than basic patent expiry.

Because the product is a small molecule, biosimilar regulation does not apply. A sponsor would pursue an abbreviated new drug application, a 505(b)(2) application for a materially different formulation or use, or a full NDA for a novel development program.

Exclusivity type	Current assessment
Composition-of-matter patent	Expired
Original hypertension indication	Open to generic competition
Pediatric exclusivity	No commercially material current protection identified
Orphan-drug exclusivity	Not established for the conventional product
New formulation exclusivity	Available only if a new product receives qualifying approval
New method-of-use exclusivity	Possible under a new NDA or 505(b)(2) strategy
Biosimilar exclusivity	Not applicable

What is the Orange Book status of mecamylamine hydrochloride?

The Orange Book should be checked for current active listings, reference-product designation, patents, and exclusivity. Historical mecamylamine products may appear with discontinued, withdrawn, or limited-market status depending on the product and listing year.

A product’s commercial availability should not be inferred solely from Orange Book presence. The Orange Book records regulatory and therapeutic-equivalence information; it does not guarantee active manufacturing, wholesaler inventory, or consistent pharmacy supply.[2]

For a new generic sponsor, the central regulatory questions are:

1. Which product is the current reference listed drug?
2. Is the reference product commercially available for bioequivalence purposes?
3. Does the FDA require a specific in vivo or in vitro bioequivalence approach?
4. Are any patents or exclusivities currently listed?
5. Is the proposed product eligible for a standard ANDA rather than a 505(b)(2) application?

What excipients are suitable for mecamylamine hydrochloride tablets?

The 2.5 mg strength creates a high drug-loading challenge in reverse. The active ingredient represents only a small fraction of the tablet, so excipient selection must support blend uniformity, segregation control, compressibility, dissolution, and manufacturing robustness.

A conventional immediate-release platform could use:

Function	Candidate excipients
Diluent	Microcrystalline cellulose, lactose monohydrate, mannitol, dibasic calcium phosphate
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate
Glidant	Colloidal silicon dioxide
Lubricant	Magnesium stearate, sodium stearyl fumarate
Taste masking	Coating polymers, ion-exchange resins, lipid barriers, polymeric microspheres
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide where permitted
Moisture control	Desiccant packaging and low-moisture excipient grades

Which excipients improve low-dose content uniformity?

For a 2.5 mg dose, geometric dilution and controlled premixing are more important than simply increasing the amount of diluent. A robust process would typically use:

• A preblend of mecamylamine hydrochloride with a portion of microcrystalline cellulose or mannitol
• A narrow particle-size distribution for the active and principal diluent
• Low-segregation granulation or ordered mixing
• Controlled lubricant addition
• In-process blend and tablet assay testing
• Unit-dose packaging if stability or supply-chain handling is problematic

Direct compression may be feasible if the active has acceptable flow and the blend remains homogeneous. Roller compaction or wet granulation may provide better content uniformity, but water exposure, residual moisture, and potential chemical stability must be evaluated.

Mannitol is attractive for orally disintegrating or chewable formats because it provides a cooling mouthfeel and lower hygroscopicity than several alternative diluents. Microcrystalline cellulose is useful for mechanical strength but can produce a less favorable mouthfeel in rapidly disintegrating tablets.

What formulations are protected or commercially attractive?

The most defensible product opportunities are differentiated dosage forms rather than a simple conventional tablet.

Orally disintegrating tablets

An orally disintegrating tablet could improve administration for patients with dysphagia or those who require supervised dosing. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and a taste-masking system could form the platform.

The principal risks are:

• Bitter or irritating taste
• Dose uniformity at very low drug load
• Drug release before swallowing
• Stability under high humidity
• Pediatric exposure concerns
• Potential for accidental administration

A rapidly disintegrating tablet should not be developed without a credible taste-masking strategy. Mecamylamine’s pharmacology makes inadvertent exposure commercially and medically consequential.

Film-coated immediate-release tablets

A small, film-coated tablet is the lowest-risk commercial formulation. The coating can reduce direct taste exposure, improve handling, and create a more consistent appearance. The formulation should avoid excessive coating weight because the 2.5 mg dose may require a small tablet and rapid dissolution.

Modified-release tablets

Modified release could reduce peak-related adverse effects and improve tolerability, but the product would require clinical bridging. A release-controlled system may also complicate dose titration because mecamylamine is used in low doses and patients may require individualized adjustment.

Potential platforms include:

• Hydrophilic matrix tablets
• Multiparticulate capsules
• Coated pellets
• Osmotic systems
• Ion-exchange resin complexes

A modified-release product has stronger potential for 505(b)(2) positioning than a standard generic. Its commercial value depends on demonstrating a clinically meaningful advantage, such as fewer blood-pressure fluctuations or improved tolerability.

Liquid oral formulations

A liquid can support dose titration and clinical research but has a narrow commercial case. Development issues include:

• Taste masking
• Chemical and microbiological stability
• Accurate dosing at very low volumes
• Compatibility with preservative systems
• Child-resistant packaging
• Risk of dosing errors

An oral solution may be useful for investigational studies, compounding substitution, or specialty pharmacies. It is less attractive as a mass-market product unless a defined patient population requires flexible dosing.

Transdermal or implantable delivery

Transdermal delivery could theoretically reduce gastrointestinal exposure and provide continuous dosing. The low daily dose is favorable from a payload standpoint, but the drug’s ionic character and skin permeability may require a permeation enhancer or prodrug approach. Such products would involve substantial development risk and likely require a full clinical program.

What method-of-use patents could support a new product?

Mecamylamine has been studied outside hypertension, including as a pharmacologic tool in nicotine dependence and neuropsychiatric research. New-use claims could target:

• Smoking cessation
• Reduction of nicotine reinforcement
• Prevention of relapse
• Treatment of stimulant or alcohol-use disorders
• Neuropsychiatric disorders involving nicotinic signaling
• Combination therapy with nicotine replacement products
• Combination therapy with varenicline, bupropion, or behavioral interventions

Method-of-use patents face several limitations. Mecamylamine’s adverse-effect profile can restrict dose selection and treatment duration. A use patent also requires a commercially viable patient population, a clinically persuasive endpoint, and a dosing regimen that is differentiated from known research use.

A 505(b)(2) pathway could be appropriate where the sponsor relies partly on existing safety and pharmacology data but proposes a new indication, formulation, or route of administration. FDA approval would still require adequate evidence for the proposed use.[3]

Which companies are challenging or competing with mecamylamine hydrochloride?

No major branded pharmaceutical company currently appears to be competing with mecamylamine as a mainstream antihypertensive. Competition comes from therapeutic substitutes rather than direct mecamylamine products.

Competitive area	Main alternatives
Hypertension	ACE inhibitors, ARBs, calcium-channel blockers, thiazide diuretics, beta blockers
Smoking cessation	Varenicline, bupropion, nicotine-replacement therapy
Nicotinic-receptor research	Cytisine, varenicline, receptor-selective investigational agents
Specialty autonomic indications	Other agents selected according to disease and receptor target

The absence of a strong branded competitor does not eliminate competitive pressure. A generic sponsor would compete against established therapies with superior prescribing familiarity, better tolerability, stronger guideline support, and broader reimbursement.

What generic entry risks exist for mecamylamine hydrochloride?

Generic entry risk is high from an IP perspective but moderate from a commercial perspective. A sponsor could face little patent opposition while still finding the market unattractive.

Paragraph IV challenges

A Paragraph IV certification is generally relevant only if the Orange Book contains an unexpired patent for the reference product. For a legacy mecamylamine tablet, the principal product and use patents are expected to be expired. A Paragraph IV dispute may arise only if a newer formulation, use, or process patent is listed.

Potential ANDA risks include:

• Unclear or inactive reference-product status
• Difficulty obtaining representative reference batches
• Low annual volume
• Sparse commercial data
• Manufacturing economics at a low unit price
• Bioequivalence variability caused by very low drug loading
• Limited wholesaler interest

Generic launch scenarios

Scenario	Commercial outcome
Single low-cost tablet generic	Limited revenue; price competition likely
Two or more generic entrants	Rapid erosion and possible supply withdrawal
Authorized or branded generic	Better control of positioning, but limited pricing power
ODT or liquid	Differentiation with higher development cost
Modified release	Potential premium pricing if clinically differentiated
Specialty-use product	Higher margin but smaller patient population
Combination product	Greater market potential but new clinical and IP requirements

How strong is the patent estate for mecamylamine hydrochloride?

The base-drug patent estate is weak because the molecule is old and the original approval predates modern patent-term structures. A new sponsor’s patent strength would depend on claim quality in five areas:

1. Formulation performance, such as rapid dissolution with verified low-dose uniformity.
2. Taste masking that remains stable during storage and releases the drug after administration.
3. Modified-release pharmacokinetics linked to improved tolerability.
4. A specific combination regimen with clinically demonstrated benefit.
5. A manufacturing process that controls impurities, polymorph, particle size, or residual solvent.

Broad claims covering “mecamylamine hydrochloride with a pharmaceutically acceptable excipient” would be vulnerable to invalidity and obviousness attacks. Narrow claims tied to measurable performance parameters would offer stronger protection, although they may be easier to design around.

What licensing deals and partnering opportunities exist?

There is no widely established current licensing market around conventional mecamylamine hydrochloride tablets. Partnering value is more likely in a repurposing program than in the legacy antihypertensive product.

Potential transaction structures include:

• License of a new-use patent to an addiction-focused company
• Co-development of an ODT or modified-release formulation
• Contract development and manufacturing for a specialty generic
• University or biotechnology collaboration for nicotinic-receptor indications
• Regional licensing for markets with limited access to smoking-cessation products
• Supply agreements for clinical-trial material

The strongest licensing proposition would combine a defined indication, a protected formulation or regimen, and clinical evidence showing a benefit over existing nicotine-dependence therapies.

What manufacturing and IP barriers affect commercial development?

Manufacturing barriers are manageable but important at the 2.5 mg strength. The critical controls are active distribution, blend segregation, tablet weight variability, dissolution, and stability.

A commercial process should assess:

• Active particle-size distribution
• Electrostatic charging
• Blend uniformity after transfer and hopper residence
• Granulation endpoint
• Lubrication sensitivity
• Tablet friability and hardness
• Assay and content uniformity
• Dissolution across pH conditions
• Long-term and accelerated stability
• Extractables and leachables from packaging
• Cleaning validation for a potent low-dose active

Excipient suppliers could create value by offering co-processed low-dose platforms, directly compressible mannitol-cellulose systems, resin-based taste-masking systems, or validated micro-dosing premixes. Those materials may support process patents and customer lock-in even when the active ingredient is unprotected.

How does mecamylamine compare with newer nicotinic-receptor products?

Mecamylamine has a distinctive mechanism but a weak commercial position in hypertension.

Factor	Mecamylamine hydrochloride	Varenicline	Nicotine replacement
Primary role	Ganglionic blockade; investigational nicotine modulation	Smoking cessation	Smoking cessation
Regulatory maturity	Legacy product	Modern approved product	Established approved category
Patent position	Largely expired	Product- and market-specific	Product-specific and often mature
Tolerability	Limited by autonomic effects	Nausea, sleep disturbance and other effects	Local or systemic nicotine effects
Formulation opportunity	ODT, modified release, combinations	Tablets, generics, specialty formats	Patches, gum, lozenges, inhalers
Commercial scale	Small	Substantial cessation market	Large consumer and pharmacy market

Mecamylamine’s advantage is mechanistic differentiation. Its disadvantages are limited prescribing familiarity, safety constraints, and the absence of a large approved market.

What revenue exposure and commercial upside are realistic?

A conventional generic mecamylamine tablet is unlikely to generate substantial revenue without an underserved market, supply shortage, or protected distribution channel. The product may still have value in:

• Specialty pharmacies
• Hospital formularies
• Clinical trials
• Research institutions
• International markets
• Compounding substitution
• Patients requiring a legacy therapy

The higher-upside strategy is a protected product for a new indication or a formulation that resolves a clear administration or tolerability problem. That approach increases development cost and regulatory risk but may create pricing power unavailable to an unprotected generic.

What is the recommended excipient and product strategy?

A staged development plan is commercially preferable.

Stage 1: Low-risk generic platform

Develop a 2.5 mg film-coated immediate-release tablet using a low-segregation blend. Prioritize:

• Microcrystalline cellulose or mannitol as the principal diluent
• Crospovidone or croscarmellose sodium as disintegrant
• Povidone or copovidone if granulation is required
• Colloidal silicon dioxide for flow
• Sodium stearyl fumarate or magnesium stearate for lubrication
• Moisture-protective packaging

Stage 2: Differentiated dosage form

Evaluate an ODT or small multiparticulate product with taste masking. The target product profile should include rapid disintegration, low mouth exposure, high assay uniformity, and simple patient titration.

Stage 3: 505(b)(2) product

Develop modified release or a new-use combination only after pharmacokinetic and tolerability data establish a clinically credible advantage. This stage should be supported by a patent strategy based on measurable release or clinical parameters.

Key Takeaways

• Mecamylamine hydrochloride’s original patent and regulatory exclusivity have expired.
• The conventional 2.5 mg tablet is primarily a low-volume generic opportunity.
• Biosimilar risk is irrelevant because mecamylamine is a small molecule.
• The principal formulation challenge is low-dose content uniformity, not active loading.
• Mannitol, microcrystalline cellulose, crospovidone, croscarmellose sodium, povidone, and moisture-protective packaging are practical starting points.
• ODT, taste-masked, liquid, multiparticulate, and modified-release products offer greater differentiation than a basic tablet.
• New-use products for nicotine dependence or other nicotinic-receptor indications would require clinical evidence and a defensible 505(b)(2) or NDA strategy.
• Patent value is likely to come from formulation, manufacturing, combination, and method-of-use claims.
• Generic launch risk is low from an exclusivity standpoint but high from a market-size and pricing standpoint.
• The most attractive commercial path is a differentiated specialty product, not an unprotected conventional tablet.

FAQs About Mecamylamine Hydrochloride Commercial Development

Is mecamylamine hydrochloride still used for hypertension?

Yes, but its use is limited. Modern antihypertensive therapies have generally replaced ganglionic blockers because of mecamylamine’s broad autonomic adverse effects.

Can mecamylamine hydrochloride be developed as a generic drug?

Yes. A sponsor may pursue an ANDA if the product can meet FDA requirements for pharmaceutical equivalence and bioequivalence against the applicable reference product.

Is mecamylamine hydrochloride approved for smoking cessation?

No. Mecamylamine has been investigated for nicotine dependence, but the conventional product’s established FDA indication is hypertension.

Which excipient is best for a 2.5 mg mecamylamine tablet?

No single excipient is universally optimal. A low-segregation diluent system based on microcrystalline cellulose, mannitol, or a combination is a practical starting point, followed by disintegrant and flow optimization.

Could an orally disintegrating mecamylamine product obtain new exclusivity?

Potentially. A qualifying new formulation may obtain regulatory exclusivity, while novel formulation or performance claims may support patent protection. The product would need a clinically and technically meaningful difference from the conventional tablet.

References

1. U.S. Food and Drug Administration. (n.d.). Mecamylamine hydrochloride prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
3. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.